FDA Oncology Announcements

MET inhibitor × Clear all

5 Announcements

FDA approves tepotinib for metastatic non-small cell lung cancer

Drug: Tepmetko (tepotinib) · MET inhibitor
Condition: Thoracic

FDA approves capmatinib for metastatic non-small cell lung cancer

Drug: Tabrecta (capmatinib) · MET inhibitor
Condition: Thoracic

FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer

Drug: Tepmetko (tepotinib) · MET inhibitor
Condition: Thoracic

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Drug: TABRECTA (capmatinib) · MET inhibitor
Condition: Thoracic

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Drug: TABRECTA (capmatinib) · MET inhibitor
Condition: Thoracic